An Observational Study of Xeljanz® (tofacitinib citrate) and Biologic Rheumatoid Arthritis Treatments to Characterize their General Treatment Patterns, Effectiveness and Safety in a Real-World Taiwanese Population

First published 11/05/2016

Last updated 23/04/2024

EU PAS number:

EUPAS13431

Study

Finalised

Documents

Study protocol

Initial protocol

A3921275_PROTOCOL_V1.0_01FEB2016 (for EU PAS register)

English (638.26 KB - PDF)View document

Updated protocol

A3921275 Non-Interventional PROTOCOL Amendment 1 (clean version 2) 16 March 2022_Redacted

First published: 22/02/2024

English (1.92 MB - PDF)View document

Study results

A3921275 Non Interventional Study Report Abstract 25 March 2022

English (109.32 KB - PDF)View document

Study report

A3921275 Non Interventional Study Report 25 March 2022_Redacted

English (2.36 MB - PDF)View document

A3921275 Non Interventional Study Report Summary of Changes 19Jul2022

English (1.24 MB - PDF)View document

Other information

Study, other information

A3921275 Non Interventional Study Protocol Abstract 16 March 2022

English (1.78 MB - PDF)View document

A3921275 Non Interventional Study Report Summary of Changes 19Jul2022.pdf

English (1.24 MB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs